All In Biotech

Drug Trial Radar · NCT07027020

Efficacy of Intravesical Oxybutynin in Children With Neurogenic Bladder Dysfunction

Efficacy of Intravesical Oxybutynin in Children With Neurogenic Bladder Dysfunction: A Randomized, Prospective Controlled Multi-center Trial

Last checked: Nov 20, 2026Latest source record: Apr 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Jan 15, 2026

Primary completion

Jan 2028

Study completion Jun 2028

Sponsor

Lead sponsor
Central Hospital, Nancy, FranceAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Ministry of Health, France; FARCO PHARMA
First posted
Jun 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 6 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Malformation of the lumbosacral region (spina bifida) affects the innervation of the bladder in children. The usual evolution leads to a neurological bladder with small capacity, poor compliancy and overactivity, exposing to incontinence and obstruction to the evacuation of urine. It is responsible for renal failure requiring dialysis and transplantation. Current therapeutics aim to evacuate urine and reduce intravesical pressure. It gradually combines 1) intermittent catheterization, 2) anticholinergics, 3) botulinum toxin (Botox®) injection into the detrusor (bladder muscle) by cystoscopy and 4) surgery (vesicostomy, Bricker, enterocystoplasty). Oxybutynin relaxes the detrusor, improves continence and reduces intravesical pressure. It is usually administered per os, but there are contraindications (glaucoma, myasthenia), side effects (constipation, dry mouth). It can be difficult to swallow for children, and drug resistance may develop. It can lead to ineffective treatment requiring therapeutic escalation. The next step, intradetrusor Botox® injection, is invasive (cystoscopy), has a limited duration of action (6 months) and must be performed under general anesthesia in children. Surgical treatments are effective but irreversible and responsible for morbidity and mortality. A randomized study was performed demonstrating the efficacy of intravesical oxybutynin compared to oral administration in adult patients. This study found a significant increase in bladder capacity and a significant decrease in side effects in the intravesical oxybutynin group. Due to the relative difficulties of intravesical oxybutynin delivery (preparation, cost) and the more invasive nature, it is not used as an alternative to oral oxybutynin. The hypothesis of this study is that this treatment may have a legitimate place in the treatment of neurogenic bladder in patients with failure of anticholinergic treatment before a therapeutic escalation requiring an invasive procedure (Botox®, enterocystoplasty) especially in children for whom repeated general anesthesia for Botox® injection may interfere with brain development. In this way, the investigators aim to extend the time to therapeutic escalation in the pediatric population. The main objective of the trial is to compare the efficacy on maximal bladder capacity of intravesical oxybutynin instillation versus placebo in the treatment of children with overactive neurogenic bladder (spina bifida), performing intermittent catheterization, for whom oral anticholinergic treatment is ineffective or poorly tolerated.

Conditions

  • Spina Bifida

Interventions

  • Oxybutynin HydrochlorideDrug

    Pharmaceutical form: solution. Route of administration: Intravesical. Medicinal product unique ID: PRD8074745. EU active substance code: SUB03581MIG.

  • PlaceboDrug

    Pharmaceutical form: solution. Route of administration: Intravesical.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evolution of maximal bladder capacity at 4 weeks of treatment (end of follow-up)Time frame: 4 weeks

Locations

19 sites in 1 country. Site status is shown where the registry gives one.

  • Centre Hospitalier Universitaire de Besançon

    Besançon, France · Not yet recruiting

  • Centre Hospitalier Universitaire De Bordeaux

    Bordeaux, France · Not yet recruiting

  • Centre Hospitalier Régional Et Universitaire De Brest

    Brest, France · Not yet recruiting

  • Centre Hospitalier Universitaire De Caen Normandie

    Caen, France · Not yet recruiting

  • Centre Hospitalier Universitaire de Clermont-Ferrand

    Clermont-Ferrand, France · Not yet recruiting

  • Centre Hospitalier De Colmar

    Colmar, France · Not yet recruiting

  • Centre Hospitalier Universitaire Grenoble Alpes

    Grenoble, France · Not yet recruiting

  • Centre Hospitalier Universitaire de Lille

    Lille, France · Not yet recruiting

  • Centre Hospitalier Et Universitaire De Limoges

    Limoges, France · Not yet recruiting

  • Centre Hospitalier Régional De Marseille

    Marseille, France · Not yet recruiting

  • Fondation Lenval Nice

    Nice, France · Not yet recruiting

  • Hôpital Necker Enfants Malades

    Paris, France · Not yet recruiting

  • Hôpital Trousseau (chirurgie viscérale pédiatrique et néonatale)

    Paris, France · Not yet recruiting

  • Hôpital Trousseau (médecine physique et de réadaptation pédiatrique)

    Paris, France · Not yet recruiting

  • Centre Hospitalier Universitaire de Poitiers

    Poitiers, France · Not yet recruiting

  • Centre Hospitalier Universitaire de Rennes

    Rennes, France · Not yet recruiting

  • Centre Hospitalier Universitaire De Saint Etienne

    Saint-Etienne, France · Not yet recruiting

  • Les Hopitaux Universitaires De Strasbourg

    Strasbourg, France · Not yet recruiting

  • Centre Hospitalier Régional Et Universitaire de Nancy

    Vandœuvre-lès-Nancy, France · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.